What is the recommended treatment for a patient with acute myeloid leukemia presenting with monosomy 7 and 52% blasts?

Treatment of AML with Monosomy 7 and 52% Blasts

For this patient with newly diagnosed AML harboring monosomy 7 (one of the most adverse cytogenetic abnormalities), immediate evaluation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) is mandatory, as this represents the only potentially curative therapy, while induction chemotherapy selection depends critically on age, fitness, and whether therapy-related or MDS-related AML is present. 1, 2

Risk Stratification

• Monosomy 7 places this patient in the ELN adverse-risk category with expected 5-year survival <23% without allo-HSCT 2
• Median overall survival with chemotherapy alone is approximately 8-12 months 2
• The 52% blast percentage confirms this is AML (≥20% blasts), not MDS, requiring AML-directed therapy 1

Immediate Diagnostic Requirements Before Treatment

Obtain these studies urgently to guide therapy selection:

• HLA typing (high-resolution molecular typing of classes I and II) of patient and available siblings immediately—do not delay this 1
• Molecular profiling for FLT3-ITD, FLT3-TKD, NPM1, IDH1, IDH2, TP53, and RAS pathway mutations 1, 3
• Assessment for therapy-related or MDS-related AML (prior cytotoxic therapy or antecedent MDS), as this fundamentally changes treatment selection 1
• Germline testing for GATA2, RUNX1, DDX41, and Fanconi anemia genes if age <50 years or suggestive clinical features 4

Induction Chemotherapy Selection Algorithm

If Age ≥60 Years AND Therapy-Related or MDS-Related AML:

CPX-351 (liposomal daunorubicin/cytarabine) is the recommended induction regimen 1

• CPX-351 improved 2-year OS from 12.3% to 31.1% in this population 1
• Dose: CPX-351 100 units/m² (daunorubicin 44 mg/m² + cytarabine 100 mg/m²) IV over 90 minutes on days 1,3,5 1

If FLT3-ITD or FLT3-TKD Positive (Any Age):

7+3 plus midostaurin unless therapy-related/MDS-related AML age ≥60 (then CPX-351 takes precedence) 1

• Cytarabine 100-200 mg/m²/day continuous infusion days 1-7 5
• Idarubicin 12 mg/m²/day IV over 10-15 minutes days 1-3 5
• Midostaurin 50 mg PO twice daily days 8-21 1

If Age <60 Years, ELN Adverse Risk, No FLT3 Mutation:

Consider FLAG-Ida or 7+3 with cladribine/fludarabine 1

• These intensified regimens may improve outcomes in younger high-risk patients 1
• Standard 7+3 (cytarabine + idarubicin as above) is acceptable alternative 1

If Age ≥60 Years, Not Fit for Intensive Chemotherapy:

Azacitidine 75 mg/m²/day subcutaneously for 7 consecutive days every 28 days 1

• Azacitidine shows particular benefit in patients with chromosome 7 alterations 1
• Continue for minimum 6 cycles to assess response 1
• Median OS 10.4 months with azacitidine in higher-risk MDS/AML 1

Critical Treatment Pitfalls

Avoid gemtuzumab ozogamicin (GO) in adverse-risk cytogenetics including monosomy 7—GO showed no benefit on 6-year OS in adverse-risk patients (6-year OS 8.9%) and is not recommended 1

Do not delay allo-HSCT evaluation—HLA typing must be initiated at diagnosis, as allo-HSCT is the only curative option with 2-year leukemia-free survival of 30% and overall survival of 36% 6

Response Assessment and Transplant Timing

• Bone marrow evaluation on day 14-21 after induction cycle 1 to assess blast clearance 1
• If ≥5% blasts persist, administer second induction cycle (same regimen or FLAG-Ida) 1
• Proceed to allo-HSCT in first complete remission if age <55 years with HLA-matched sibling donor 4
• For patients age 55-70 years, matched unrelated donor transplant should be considered 1

Consolidation Before Transplant

If 2-6 cycles of chemotherapy needed as bridge to transplant:

• Continue same induction regimen or switch to intermediate-dose cytarabine 1
• If CPX-351 used for induction, continue CPX-351 for consolidation 1
• If azacitidine used, continue azacitidine until transplant 1

Additional Prognostic Considerations

TP53 mutation status critically impacts outcomes:

• TP53 mutations occur in 67% of monosomy 7 AML and persist in 97% at relapse 3
• Median OS only 8.6 months with TP53 mutation versus 13.04 months without 3
• Allo-HSCT improves OS significantly regardless of TP53 status 3

Complex karyotype worsens prognosis further:

• Median OS 8.6 months with complex karyotype versus 12.4 months without 3
• Presence of monosomal karyotype, -5/5q-, abn(17p), or inv(3) alongside monosomy 7 identifies extremely poor prognosis subgroup even after transplant 6